TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$30 Million

Ovid Therapeutics

Follow-on Offering

Lead Left Bookrunner, February 2019

Ovid Therapeutics
Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. The Company's most clinically-advanced product candidate, OV101, is a first-in-class ?-selective GABAA receptor agonist. OV101 is currently Phase III ready in Angelman syndrome (AS). Ovid announced positive topline Phase II data in adult and adolescent AS in August 2018 that achieved its primary endpoint of safety and tolerability (n=88). Exploratory efficacy data from the study showed a statistically significant improvement in CGI-I score with improvements in sleep, motor and behavioral symptoms that support the potential of OV101. In December 2018, the Company announced plans to move forward with a Phase III OV101 trial in pediatric patients with AS based on a successful End-of-Phase II meeting with the FDA. The pivotal Phase III NEPTUNE study is expected to initiate 2H 2019. The Company also initiated a Phase II trial of OV101 in Fragile X syndrome (FXS) in July 2018 with data anticipated in 2H 2019